Explore
Trendline
IDEAYA Biosciences to Present Phase 2/3 Trial Data on Darovasertib at ASCO 2026
IDEAYA Biosciences to Present Phase 2/3 Trial Data on Darovasertib at ASCO 2026
Read More
Trendline
Forlong Biotechnology to Present Clinical Data on FL115 at ASCO 2026
Forlong Biotechnology to Present Clinical Data on FL115 at ASCO 2026
Read More
Trendline
Dizal to Present Key Developments in NSCLC Treatments at ASCO 2026
Dizal to Present Key Developments in NSCLC Treatments at ASCO 2026
Read More
Trendline
Incyte Presents Phase 3 Tafasitamab Data at ASCO 2026, Supporting Global Submissions
Incyte Presents Phase 3 Tafasitamab Data at ASCO 2026, Supporting Global Submissions
Read More
Trendline
Pfizer Showcases Oncology Innovations at ASCO 2026, Highlighting New Standards of Care
Pfizer Showcases Oncology Innovations at ASCO 2026, Highlighting New Standards of Care
Read More
Trendline
Inhibrx Announces Webcast for Clinical Update on Ozekibart in Colorectal Cancer
Inhibrx Announces Webcast for Clinical Update on Ozekibart in Colorectal Cancer
Read More
Trendline
Obsidian Therapeutics to Present Phase 2 Data on OBX-115 for Advanced Melanoma at ASCO 2026
Obsidian Therapeutics to Present Phase 2 Data on OBX-115 for Advanced Melanoma at ASCO 2026
Read More
Trendline
Immunitas Therapeutics Presents Promising Data on IMT-009 at AACR 2026
Immunitas Therapeutics Presents Promising Data on IMT-009 at AACR 2026
Read More
Trendline
Debiopharm's Ovarian Cancer Treatment Receives FDA Fast Track Designation
Debiopharm's Ovarian Cancer Treatment Receives FDA Fast Track Designation
Read More
Trendline
EpiBiologics Initiates Phase 1 Study of EPI-326 for EGFR-Driven Cancers
EpiBiologics Initiates Phase 1 Study of EPI-326 for EGFR-Driven Cancers
Read More
Trendline
NEOK Bio Highlights Bispecific Antibody Drug Conjugate Pipeline at AACR 2026
NEOK Bio Highlights Bispecific Antibody Drug Conjugate Pipeline at AACR 2026
Read More
Trendline
Salubris Biotherapeutics Unveils Phase 1/2 Data for JK06 Antibody Drug Conjugate at AACR Meeting
Salubris Biotherapeutics Unveils Phase 1/2 Data for JK06 Antibody Drug Conjugate at AACR Meeting
Read More
